Atopic dermatitis, psoriasis, and other inflammatory skin diseases are a constant topic of discussion at national dermatological conferences as new treatment options are approved and studied.in an interview with Dermatology Times®Raj Chovatiya, MD, PhD, Assistant Professor of Dermatology, Director of the Eczema Itching Center, Medical Director of the Clinical Trials Division of Dermatology at Northwestern University Feinberg School of Medicine, and Dermatology Times® A member of the Editorial Advisory Board, he highlights the sessions “Managing Inflammatory Disease: Practical Tips,” “Freeing Patients from Prurigo Nodularis,” and “Clear Choices for Topical Treatment of Plaque Psoriasis.” sharing.
Transcription:
Raj Chovatiya, MD, PhD: hello. I’m Raj Chovatiya, Ph.D., Northwestern University Feinberg School of Medicine in Chicago, Illinois. He is an Assistant Professor, Director of the Eczema Itch Center, and Head of Clinical Medicine. A clinical trial unit for dermatology.I am also a member of the Editorial Advisory Board Dermatology TimesWe are so excited to bring you a preview of the Winter Clinical Hawaii Meeting! There are many opportunities to participate in very fun, exciting and innovative sessions, but what I really wanted to highlight was the entire discussion panel on Inflammatory Diseases. You’ll see the two groups go back and forth in a bit of a debate style about some of the hottest questions we have in mind related to hidradenitis and even hidradenitis. Whether you decide to be human or verbal human, how do you feel about laboratory monitoring and what scores do you prefer to use in a clinical setting? Also what is the most important thing in the inspection and it will cover all of them so it will be very fun and interactive for the whole audience. The session talks about helping patients with pruritus nodosa. One inch at a time. Although PN has been a relatively under-discussed disease for many years, there has been a great deal of groundbreaking research in the last few years, resulting in significant clinical and therapeutic improvements. I have the opportunity to talk about some of the burdens, some of the diagnoses, and the big leaps we’ve made in terms of actually FDA-approved treatments and some new treatments that are in the works. Other sessions on offer include treatment updates as far as JAK inhibitors address atopic dermatitis and topical innovations in the case of psoriasis. See you.
Edited transcript for clarity
